ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2762

Smoking and Severity of Psoriatic Arthritis

Sahithi Jarugula1, Bonita Libman2, Amanda Kennedy3 and Diantha Howard4, 1Internal Medicine, Sahithi Jarugula, S.Burlington, VT, 2Internal Medicine, University of Vermont Medical Center, Burlington, VT, 3Internal Medicine, University of Vermont Medical center, Burlington, VT, 4Statistics, University of Vermont, Burlington, VT

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: psoriatic arthritis and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Smoking is a major modifiable risk factor for various inflammatory diseases including rheumatoid arthritis 1, 2 and psoriasis 3,4,5. The presence of cyclic citrullinated peptide antibody (CCP) has been associated with smoking in rheumatoid arthritis 1. Presence of CCP has also been shown to be associated with severe Psoriatic arthritis (PsA) in a few retrospective studies 6,7. Our aim is to assess the association of smoking and CCP Ab positivity in PsA, with the hypothesis that smoking is associated with severe PsA, and CCP may also be associated with severe arthritis.

Methods: Medical records of patients with PsA followed in our clinic from 2010 to 2015, identified by ICD 9 code were analyzed for demographic characteristics, body mass index (BMI), smoking status, CCP positivity and clinical characteristics for severe PsA. Severe disease was defined as treatment with biologics and/or joint erosions identified on hand and foot radiographs. Chi square statistic was used to assess the relationship between smoking and disease severity. The association of CCP positivity with severe PsA was determined by Fisher’s exact test.

Results: One hundred and twelve patients who were ever smokers and one hundred and thirteen never smokers were identified. 30.4% were found to have more severe disease in the ever smoker group and 36.3% were found to have more severe disease in the never smoker group with a relative risk of 0.84 (0.58-1.21, 95% CI)

Conclusion: A relationship between smoking status and disease severity was not identified. There were insufficient numbers of CCP positive patients to establish statistical significance for either positive association with smoking or disease severity. However, CCP positive patients were more likely to be on biologic medications, further studies are needed to establish relationship. References: 1. Klareskog et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to auto antigens modified by citrullination. Arthritis and Rheumatism 2006;54:38–46 2. Stolt et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis:results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-841 3. Mills et al. Smoking habits in Psoriasis: a case control study. British Journal of dermatology 1992;127:18-21 4. Setty et al. Smoking and risk of Psoriasis in Women: Nurses’ Health Study II. Am J Med 2007;120:953-959 5. Armstrong et al. Smoking and pathogenesis of Psoriasis: a review of oxidative, inflammatory and genetic mechanisms. British Journal of dermatology 2011;165:1162-1168 6. Bogliolo et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. Jrheum 2005; 32:511-515 7. Perez-Alamino et al. Are anti CCP antibodies in Psoriatic arthritis patients a biomarker of erosive disease. J Med Life 2013;6(4):376-82


Disclosure: S. Jarugula, None; B. Libman, Novartis Pharmaceutical Corporation, 2; A. Kennedy, None; D. Howard, None.

To cite this abstract in AMA style:

Jarugula S, Libman B, Kennedy A, Howard D. Smoking and Severity of Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/smoking-and-severity-of-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-and-severity-of-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology